Modern oncology has largely been built on a reductionist model: identify a dominant pathway, target it with precision, and expect tumor regression. Yet cancer has repeatedly demonstrated that it is not a disease of isolated pathways, but of adaptive biological systems. Tumors do not fail because a single pathway is inhibited—they evolve.
This realization has driven increasing interest in systems-level therapeutic strategies, particularly those targeting cancer metabolism. The concept of the multi-axis metabolic trap represents one such approach. Rather than focusing on a single vulnerability, it imposes coordinated stress across multiple metabolic and signaling domains, with the goal of inducing metabolic inflexibility—a state in which tumor cells can no longer adapt.
Within this framework, most agents exert pressure on a defined axis: glucose metabolism, mitochondrial function, mitosis, stress signaling, or redox regulation. However, one agent does not fit neatly into this schema.
Ivermectin occupies a unique role.
It is not best understood as a single-target drug, nor even as a conventional multi-target agent. Rather, ivermectin functions as a network-level amplifier, linking and reinforcing multiple axes of the metabolic trap simultaneously. This property may explain why it demonstrates disproportionate synergy in combination, despite relatively modest activity as a monotherapy.